ZeJing Pharma's Thyroid Cancer Treatment Trial Meets Primary EndpointCoinLive·May 7 at 03:43 AM688266-0.25%
Zelgen: The Phase III clinical trial of Hydrochloride Gikaxitin Tablets for the treatment of active ankylosing spondylitis has reached the primary efficacy endpointZhitong·Oct 20, 2025 at 03:34 AM688266-0.25%
3 Global Growth Companies With High Insider Ownership Expecting 38% Revenue GrowthSimplywall·Sep 30, 2025 at 08:40 AM300811+0.54%688266-0.25%
Zelgen: Injectable ZGGS34 has received approval for clinical trialsZhitong·Sep 17, 2025 at 03:14 AM688266-0.25%
Zelgen: Injectable ZG006 initiates key clinical trials and completes enrollment of the first subjectZhitong·Sep 16, 2025 at 02:48 AM688266-0.25%
Zelgen: Clinical data for ZG006 and ZG005 released at the 28th Annual Academic Conference of the Chinese Society of Clinical Oncology (CSCO)Zhitong·Sep 11, 2025 at 02:50 AM688266-0.25%
Zelgen: Clinical trials for injectable ZG005, injectable ZGGS18, and hydrochloride gilteritinib tablets combined for advanced solid tumors have been approvedZhitong·Aug 21, 2025 at 06:01 AM688266-0.25%
Zelgen: Injectable ZG005 combined with Hydrochloride Gilteritinib Tablets and chemotherapy has received approval for clinical trialsZhitong·Aug 20, 2025 at 03:43 AM688266-0.25%
Zelgen: The clinical trial application for injectable ZGGS34 has been approved by the FDAZhitong·Aug 19, 2025 at 03:50 AM688266-0.25%
Zelgen rose by 0.72%, reaching 133.97 yuan per share, with the stock price hitting a new high. The total market value exceeded 35.462 billion yuan, and the trading volume reached 245 million yuanZhitong·Jul 18, 2025 at 01:48 AM688266-0.25%
Zelgen: Injectable ZG006 included in the list of breakthrough therapy designationsZhitong·Jul 10, 2025 at 04:26 AM688266-0.25%
The chemical pharmaceutical sector sees a short-term surge, ALK hits the limit upZhitong·Jun 19, 2025 at 09:34 PM688266-0.25%300584+0.56%
Zelgen: Injection ZG005 and Injection ZG006 combination receives approval for clinical trialsZhitong·Jun 17, 2025 at 02:43 AM688266-0.25%
Zelgen signed an exclusive marketing service agreement for injectable recombinant human thyroid-stimulating hormoneZhitong·Jun 5, 2025 at 02:44 AM688266-0.25%
